Gemin X Biotechnologies

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

54 documents for Gemin X Biotechnologies

- Tripos Discovery Research, a Subsidiary of Commonwealth Biotechnologies, Inc., Secures a Discovery Milestone Payment from Gemin X Biotechnologies Inc.
RICHMOND, Va. & MONTREAL & BUDE, England -- Tripos Discovery Research (TDR) Limited, a wholly owned subsidiary within the Commonwealth Biotechnologies...
- Business Wire
- August 07, 2007
- Gemin X Biotechnologies Initiates Phase 2 Clinical Trial Program for GX15-070 in Myelofibrosis and Hodgkin's Lymphoma.
MONTREAL -- Gemin X Biotechnologies Inc. announced today the initiation of a Phase 2 clinical trial program to evaluate GX15-070 in the treatment of s...
- Business Wire
- September 14, 2006
- Gemin X Biotechnologies Secures U.S. $65.2 Million in Financing; Funds Will Drive Clinical Development of Targeted Oncology Drugs.
MONTREAL -- Gemin X Biotechnologies Inc., a privately held biotechnology company developing novel cancer treatments based on the regulation of apoptos...
- Business Wire
- May 19, 2005

- Review of Clinical Data from Gemin X Biotechnologies' GX15-070 Program Presented at the 24th Annual Chemotherapy Foundation Symposium.
MONTREAL -- Gemin X Biotechnologies Inc. announced today that a review of Phase 1 clinical data obtained with the company's lead product candidate, GX...
- Business Wire
- November 09, 2006
- Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma.
MONTREAL -- Gemin X Biotechnologies Inc. announced today that a report published in the journal Blood demonstrated that its lead compound, obatoclax (...
- Business Wire
- May 15, 2007
- Gemin X Biotechnologies Initiates Phase 1 Clinical Trial with Novel Cancer Drug Candidate GX15-070.
MONTREAL -- First Small Molecule Inhibitor of Bcl-2 Proteins to Enter the Clinic Selectively Induces Natural Cell Death in Multiple Types of Cancers ...
- Business Wire
- November 04, 2004
- Gemin X Biotechnologies Hires Jean Viallet, M.D., Former Group Director of Clinical Development and Medical Affairs at GlaxoSmithKline, as VP of Clinical Development.
Business Editors/Health/Medical Writers BIOWIRE2K MONTREAL, CANADA--(BUSINESS WIRE)--Feb. 20, 2003 Gemin X Biotechnologies Inc., a Montreal-base...
- Business Wire
- February 20, 2003
- Gemin X Biotechnologies to Present at the 25th Annual JPMorgan Healthcare Conference.
MONTREAL -- Gemin X Biotechnologies Inc. announced today that Dan Giampuzzi, the Company's president and chief executive officer, will present an over...
- Business Wire
- December 21, 2006
- Gemin X Biotechnologies Initiates Phase 1/2 Clinical Trial with GX15-070 in Chronic Lymphocytic Leukemia; FDA Grants Orphan Drug Designation for GX15-070 in CLL.
MONTREAL -- Gemin X Biotechnologies Inc. announced today the initiation of a Phase 1/2 clinical trial in chronic lymphocytic leukemia (CLL) with GX15-...
- Business Wire
- January 06, 2005
- Gemin X Biotechnologies to Webcast Presentation at BIO CEO & Investor Conference.
Business Editors/Health/Medical Writers BIOWIRE2K BIO CEO & Investor Conference MONTREAL--(BUSINESS WIRE)--Feb. 19, 2004 Gemin X Biotechnologi...
- Business Wire
- February 19, 2004